Anti-tumor activity of transduced T cells in vivo.

<p><b>(A)</b> Schema of in vivo study demonstrating the anti-CD20 anti-tumor activity of transduced T cells in a disseminated human B cell malignancy xenogeneic NOD/SICD model. Raji-FFLuc tumor cells were injected i.v. into NOD/SCID mice on day 0. Two doses (5×10⁶ million cells per dose) of either iC9-CD20CAR- Δ19 transduced T cells or non-transduced T cells were injected i.v. on day 2 and day 9 respectively. Whole mouse luciferase activity was measured at various time points. (<b>B</b>) Eradication of CD20⁺ Raji tumors in NOD-SCID mice by CD20-CAR T cells but not non-transduced T cells (Mock T) as measured by in vivo bioluminescent imaging. (<b>C</b>) Summary of the bioluminescence signal as a measurement of tumor growth by days after tumor cell infusion. Data represent mean + SD. (<b>D</b>) Kaplan-Meier survival curves of mice receiving iC9-CD20CAR-Δ19 T treatment (CD20-CAR T) or non-transduced mock T cell treatment (NT).